NCT03854617View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

February 20, 2019

Primary Completion Date

December 20, 2021

Study Completion Date

December 20, 2025

Conditions
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions
DRUG

Oral NVB Metronomic

50mg three times weekly on Mondays (or Tuesdays), Wednesdays (or Thursdays) and Friday (or Saturdays). A cycle is a 3 weeks period.

DRUG

Oral NVB Weekly

60mg/m2 weekly for cycle 1 and 80mg/m2 weekly for subsequent cycles in the absence of grade 3 or 4 toxicity. A cycle is a 3 weeks period

All Listed Sponsors
lead

Chinese Academy of Medical Sciences

OTHER